Where Sources Agree

• arrows_inputFirst MDMA Prescribing Approval: Predominant reporting shows Medsafe has authorized two psychiatrists, Dr. Gary Wynn and Dr. Tom Paterson, to prescribe pharmaceutical-grade MDMA for PTSD treatment; this represents the first time the regulator has granted such authority, according to official statements.
• arrows_inputClinical Safety Protocols: Several outlets confirm that MDMA treatment for PTSD must occur within a controlled clinical setting with no take-home doses permitted and is restricted to patients aged 18 or older, according to Ministry of Health guidelines.
• arrows_inputTreatment Costs and Course: A portion of reporting indicates a standard course of MDMA-assisted therapy involves three rounds of treatment at approximately $15,000 per round, with no public funding currently allocated, according to medical reporting.

Where Sources Disagree

• arrows_outputRegulatory Context Reporting: Some reports include the context of the US FDA's 2024 rejection of MDMA therapy, citing safety and effectiveness concerns. Conversely, other outlets focus exclusively on New Zealand's recent approval, omitting the American regulatory decision.
• arrows_outputTreatment Cost and Accessibility: Some reports highlight the projected costs of MDMA-assisted therapy, estimating about $15,000 per treatment round, while other outlets focus on the regulatory approval process and clinical safeguards without mentioning potential financial barriers or accessibility limitations.